Clinical Trial Update: The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment [Phase 2]

View source ↗

Summary

Phase II trial evaluating the value of radiotherapy in combination with erlotinib as second-line treatment for oligometastatic non-squamous non-small cell lung …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Wu Jieping Medical Foundation | Conditions: Non Small Cell Lung Cancer, Oligometastatic | Phase 2 | Status: UNKNOWN